- Home
- VTYX vs CFBK Comparison
VTYX vs CFBK Comparison
Compare VTYX & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- CFBK
- Stock Information
- Founded
- VTYX 2018
- CFBK 1892
- Country
- VTYX United States
- CFBK United States
- Employees
- VTYX N/A
- CFBK N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- CFBK Major Banks
- Sector
- VTYX Health Care
- CFBK Finance
- Exchange
- VTYX Nasdaq
- CFBK Nasdaq
- Market Cap
- VTYX 154.9M
- CFBK 154.3M
- IPO Year
- VTYX 2021
- CFBK 1998
- Fundamental
- Price
- VTYX $2.58
- CFBK $23.53
- Analyst Decision
- VTYX Buy
- CFBK Buy
- Analyst Count
- VTYX 4
- CFBK 1
- Target Price
- VTYX $11.33
- CFBK $29.00
- AVG Volume (30 Days)
- VTYX 1.1M
- CFBK 13.0K
- Earning Date
- VTYX 08-15-2025
- CFBK 08-04-2025
- Dividend Yield
- VTYX N/A
- CFBK 1.37%
- EPS Growth
- VTYX N/A
- CFBK 36.66
- EPS
- VTYX N/A
- CFBK 2.77
- Revenue
- VTYX N/A
- CFBK $52,793,000.00
- Revenue This Year
- VTYX N/A
- CFBK $35.39
- Revenue Next Year
- VTYX N/A
- CFBK $10.11
- P/E Ratio
- VTYX N/A
- CFBK $10.21
- Revenue Growth
- VTYX N/A
- CFBK 20.91
- 52 Week Low
- VTYX $0.78
- CFBK $19.23
- 52 Week High
- VTYX $3.39
- CFBK $31.17
- Technical
- Relative Strength Index (RSI)
- VTYX 46.35
- CFBK 43.19
- Support Level
- VTYX $2.63
- CFBK $23.26
- Resistance Level
- VTYX $2.92
- CFBK $23.89
- Average True Range (ATR)
- VTYX 0.22
- CFBK 0.36
- MACD
- VTYX -0.08
- CFBK -0.06
- Stochastic Oscillator
- VTYX 0.00
- CFBK 28.57
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.